foxo4-dri senolytic peptide human trial 2024 2025 Senotherapy for chronic lung disease Senescent cells as a target
Senescent cells as a target for anti aging interventions: From senolytics to immune therapies PMC Heterogeneity of Cellular Senescence, Senotyping, and Targeting by Senolytics and Senomorphics in Lung Diseases[v1] CHK2 USP37 axis stabilizes FOXO4 to sustain senescence and evade apoptosis PNAS The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4 DRI Nature Communications
Pay in 4 interest-free payments of $7.26 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16



